Nanorobotic Analytical Systems in Pharmaceutical Sciences: Translational Advances, Patents and Next-Generation Sensing Platforms

The growing molecular complexity of pharmaceuticals and biological systems poses challenges for conventional analytical methods, especially in obtaining real-time, ultrasensitive, spatially resolved, and decentralized measurements. This review examines the emerging role of nanorobotic analytical systems in pharmaceutical analysis, with an emphasis on their sensing, propulsion, actuation, navigation, and feedback capabilities.

Structured literature and patent literature analyses were carried out to assess nanorobotic analytical platforms, nanoscale sensing approaches, analytical methods, pharmaceutical applications, and technological advances. A specific focus on distinguishing between passive nanomaterials and nanorobotic systems, as well as patent landscape analysis, has been made.

The reviewed literature demonstrates advances in the areas of enzyme-driven nanomotors, magnetically controlled nanorobots, DNA-based nanorobotic systems, nanoscale biosensors, and stimuli-responsive analytical platforms. The integration of microfluidics, lab-on-a-chip technologies, and artificial intelligence has expanded the potential for automated molecular detection, real-time monitoring, high-throughput screening, and pharmaceutical analysis.

Nanorobotic analytical systems offer potential benefits through the integration of molecular recognition, controlled motion, sensing, actuation, and programmable responses within miniaturized platforms. However, many reported systems are considered nanomaterial-enabled sensors or nanomotors rather than fully autonomous analytical nanorobots. The major challenges include scalable fabrication, reproducibility, standardization, biosafety, regulatory acceptance, and validation.

Nanorobotic analytical systems represent an emerging analytical approach with potential applications in pharmaceutical quality assessment, molecular analysis, drug monitoring, and automated screening. Further advances in intelligent control, microfluidics, sensing, and artificial intelligence may facilitate their transition toward more autonomous and clinically relevant analytical platforms.